Glioblastoma Treatment Drugs Market Trends and Dynamic Demand by 2032


 During the forecast period, the Glioblastoma Treatment Drugs Market is anticipated to grow at a CAGR of 5.7%. By 2022, the market is anticipated to be worth US$ 723.30 million, and by 2032, it is anticipated to be worth US$ 1,259.13 million.

Patients have started getting clinical trials with development agents. Biomarkers are more successful regarding personalized medicine. There is a likelihood of tumor getting located in spinal cord, which does represent close to 15% of all sorts of primary brain tumors. This actually drives the demand pertaining to glioblastoma treatment drugs.

Request Sample Report: https://www.futuremarketinsights.com/reports/sample/REP-GB-1248?utm_source=4018419&utm_medium=Sanket

Drugs that are involved in the treatment of glioblastoma are antineoplastic cytotoxic drugs. This is amongst the remarkable developments in the chemotherapy drugs for treating malignant tumors. Every passing year sees an influx of new drugs for overcoming blood-brain barrier. Manufacturers are on the toes. In other words, they are into extensive research regarding upgradation of drugs to treat glioblastoma.

Variation in treatment approach of patient to patient resulting in tumor heterogeneity is actually expected to account for rise in demand for ‘personalized treatment approach’ for managing glioblastoma multiforme. New treatments are on the way, and expected to increase the life-span of the patients contracting glioblastoma multiforme. Along these lines, the US FDA, in July 2020, did grant ‘fast track designation’ to DB102 (enzastaurin) from Denovo Biopharma to treat the patients who are diagnosed with this disease.

Radiation therapy holds more than 30% of the market share due to enhanced rates of survival. Using temozolomide with radiotherapy does increase the tumor’s sensitivity to radiation. So, it’s advisable to avoid it.

It also needs to be considered that glioblastoma is aa complex disease, which says that its treatment does involve numerous approaches combining several treatments. Not all the economies have a good understanding of the ailment. As such, they can’t boast of efficient treatment. This would, in turn, be highly dependent on the investment being put in. It’s actually to wait and watch the entire thing. Future Market Insights has walked through these facts with future perspectives in its latest market study entitled ‘Glioblastoma Treatment Drugs Market’.

Key Takeaways from Glioblastoma Treatment Drugs Market

  • North America holds more than 30% of the market share and the status quo is expected to remain the same even in the forecast period. This could be credited to the US alone being home to18K people diagnosed with glioblastoma.
  • Europe holds the second-largest market share. It, in fact, contributes for 27% of the revenue. As of now, 25K cases have been reported till date. The UK is leading from the front.
  • The Asia-Pacific is expected to witness the fastest growth in glioblastoma treatment drugs market with benevolence amongst the population.

Competitive Landscape

  • Merck company, in 2019, completed acquisition of Peloton Therapeutics (a bio-therapeutic clinical-stage organization) for helping in treatment of brain cancer. A small molecule has been strongly developed for treating hypoxia-inducible factor- 2α (HIF-2α).
  • Lineage Cell Therapeutics inked a licensing deal with Immunomic Therapeutics in April 2021 to create allogeneic VAC cancer immunotherapy platform (used for treating glioblastoma multiform). As per the deal, Lineage received US$ 2 Mn payment upfront, along with US$ 67 Mn in the commercial milestone payments.

“Growing occurrences of brain tumors are likely to take the glioblastoma treatment drugs market by storm in the near future”, says an analyst from Future Market Insights.

What’s the enclosure with glioblastoma treatment drugs market?

  • Future Market Insights offers an exclusive perspective and various real-time insights on the glioblastoma treatment drugs market in its latest study, presenting historical demand assessment of 2016 – 2021 and projections for 2022 – 2032.
  • The research study is based on drug class (antineoplastic, VEGF/VEGFR inhibitors, alkylating agents, and miscellaneous antineoplastic), and by distribution channel (hospitals, cancer research organizations, long term care centers, and diagnostic centers).
  • With increasing incidences of cancer coupled with rising geriatric population, the global glioblastoma treatment drugs market is likely to grow in an aplomb in the near future.

Key Players in the Glioblastoma Treatment Drugs Market are

  • F. Hoffmann-La Roche AG,
  • Merck & Co., Inc.,
  • Sandoz
  • Arbor Pharms LLC.
  • Emcure Pharmaceuticals Ltd.
  • Bristol-Myers Squibb Company
  • Sigma-Tau Pharmaceuticals, Inc.

Key Segments:

Based on the Drug Class:

  • Antineoplastic
  • VEGF/VEGFR Inhibitors
  • Alkylating Agents
  • Miscellaneous Antineoplastic

Based on the Distribution Channel:

  • Hospitals
  • Cancer Research Organizations
  • Long Term Care Centers
  • Diagnostic Centers

By Region:

  • North America
  • Latin America
  • Asia Pacific
  • MEA
  • Europe

Comments

Post a Comment

Popular posts from this blog

Teleradiology Services Market Analysis And Demand With Forecast Overview To 2032

Image
 In 2022, it is expected that the Teleradiology Services Market would be worth around US$ 31,880.57 Million. By 2032, it is anticipated that the market for teleradiology services would reach US$5,598.3 Million. with a 19% CAGR growth forecast through 2032. The global Teleradiology Services Market is estimated to reach a market valuation of US$ 1,971.4 Million by the end of 2016 and register a CAGR of 21.0% over the forecast period (2016–2026). The growth of this market can be attributed to the favorable government initiatives regarding the adoption of teleradiology in order to provide early disease diagnosis. Besides, the application of modern-day technologies such as the adoption of cloud-based technologies, blockchain, and cryptocurrencies will lead to better efficiency and cost-effective solutions. Increasing Investments for the development of advanced solutions is augmenting the demand for the industry. Request Sample PDF Brochure: https://www.futuremarketinsights.com/reports/...
Read more

Non-Vascular Stents Market to 2032 – Global Analysis and Forecasts by Types, Technologies, Applications and End-User Verticals

Image
 The Non-Vascular Stents Market is expected to grow at a CAGR of  4.5%  over the forecast period. (2022 - 2032). The sector is expected to be valued at  US$ 1.21 billion  in 2022 and  US$ 1.9 billion by 2032. The global non-vascular stents market is expected to move forward in response to the growing demand for minimally-invasive procedures. Rising technological and material advancements are assisting in the development of specially designed stents for use in a variety of indications thereby fueling the overall non-vascular stents market growth. Non-vascular stents use small, precise incisions, resulting in scars that are smaller and less visible than those left by traditional surgical techniques, putting the patient's safety in jeopardy. The above-mentioned feature is anticipated to provide impetus to the non-vascular stents market adoption trends in coming years. Such a surgery is associated with a faster recovery period, resulting in a shorter hospital ...
Read more

From X-rays to AI: Veterinary Imaging Innovations of the Next Decade By 2022 to 2030

Image
  Between 2022 and 2030, the global veterinary imaging industry is expected to grow at a CAGR of 6.6%, from US$ 2.02 billion in 2022 to US$ 3.37 billion by 2030. A study by Future Industry Insights (FMI) predicted that by 2030, the worldwide veterinary imaging industry would bring in US$ 3.37 billion. The research study looks at the market development for veterinary imaging through 2030 in more than 20 nations. The report offers precise insights into some of the key players in the industry's crucial business strategies. According to the poll, investments are being made in the veterinary diagnostics industry as the trend towards pet humanization picks up speed. Additionally likely to fuel industry growth are governmental rules and a greater emphasis on preserving animal health. Request A Report Sample To Gain Comprehensive Insights! https://www.futuremarketinsights.com/reports/sample/rep-gb-12368 Growth will also be fueled by the expansion of the animal and pet care industry as a w...
Read more